Overview
- Sun Pharma and Organon signed a definitive deal Monday that sets a $14-per-share all-cash buyout valuing Organon at $11.75 billion including debt.
- The combined company would generate about $12.4 billion in revenue and rank among the top 25 drugmakers with a stronger focus on women’s health and biosimilars.
- Sun Pharma plans to put in $2 billion to $2.5 billion of cash and finance the balance with committed bank loans.
- Closing is slated for early 2027 subject to regulatory clearances and a vote by Organon shareholders, with the merger structured so Organon remains the surviving legal entity.
- Organon shares rose about 46% across two sessions after reports and confirmation, and Sun Pharma gained roughly 5% to 7% in Monday trading as investors weighed scale and execution.